Regulation of IL-35, IL-39 and IL-27 in tumor microenvironment

Abstract

Liu Saisai, Yuan Dongya. Regulation of IL-35, IL-39 and IL-27 in tumor microenvironment[J]. Journal of International Oncology, 2021, 48(4): 212-215.

References32

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. DOI: 10.3322/caac.21551. doi:10.3322/caac.v69.1
[2]	Teymouri M, Pirro M, Fallarino F, et al. IL-35, a hallmark of immune-regulation in cancer progression, chronic infections and inflammatory diseases[J]. Int J Cancer, 2018, 143(9):2105-2115. DOI: 10.1002/ijc.31382. doi:10.1002/ijc.v143.9
[3]	Huang C, Li N, Li Z, et al. Tumour-derived interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression[J]. Nat Commun, 2017, 8:14035. DOI: 10.1038/ncomms14035. doi:10.1038/ncomms14035
[4]	Wang K, Gong H, Chai R, et al. RETRACTED: aberrant frequency of IL-35 producing B cells in colorectal cancer patients[J]. Cytokine, 2018, 102:206-210. DOI: 10.1016/j.cyto.2017.10.011. doi:S1043-4666(17)30316-2pmid:29054723
[5]	Yang M, Zhang Z, Chen J, et al. Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity[J]. J Exp Clin Cancer Res, 2019, 38(1):351. DOI: 10.1186/s13046-019-1326-5. doi:10.1186/s13046-019-1326-5
[6]	Hao S, Chen X, Wang F, et al. Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells[J]. Carcinogenesis, 2018, 39(12):1488-1496. DOI: 10.1093/carcin/bgy136. doi:10.1093/carcin/bgy136
[7]	Heim L, Kachler K, Siegmund R, et al. Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer[J]. Br J Cancer, 2019, 120(9):903-912. DOI: 10.1038/s41416-019-0444-3. doi:10.1038/s41416-019-0444-3
[8]	Larousserie F, Kebe D, Huynh T, et al. Evidence for IL-35 expression in diffuse large B-cell lymphoma and impact on the patient's prognosis[J]. Front Oncol, 2019, 9:563. DOI: 10.3389/fonc.2019.00563. doi:10.3389/fonc.2019.00563pmid:31316915
[9]	Zhu J, Yang X, Wang Y, et al. Interleukin-35 is associated with the tumorigenesis and progression of prostate cancer[J]. Oncol Lett, 2019, 17(6):5094-5102. DOI: 10.3892/ol.2019.10208.
[10]	Takahashi R, Macchini M, Sunagawa M, et al. Interleukin-1β-induced pancreatitis promotes pancreatic ductal adenocarcinoma via B lymphocyte-mediated immune suppression[J]. Gut, 2021: 70(2):330-341. DOI: 10.1136/gutjnl-2019-319912.
[11]	Zhang X, Zhang Z, Ju M, et al. Pretreatment with interleukin 35-engineered mesenchymal stem cells protected against lipopolysaccharide-induced acute lung injury via pulmonary inflammation suppression[J]. Inflammopharmacology, 2020, 28(5):1269-1281. DOI: 10.1007/s10787-020-00696-5. doi:10.1007/s10787-020-00696-5
[12]	Li X, Fang P, Sun Y, et al. Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells[J]. Redox Biol, 2020, 28:101373. DOI: 10.1016/j.redox.2019.101373. doi:10.1016/j.redox.2019.101373
[13]	Carvalho MI, Pires I, Prada J, et al. Assessing the interleukin 35 immunoexpression in malignant canine mammary tumors: association with clinicopathological parameters and prognosis[J]. Anticancer Res, 2019, 39(4):2077-2083. DOI: 10.21873/anticanres.13319. doi:10.21873/anticanres.13319
[14]	Turnis ME, Sawant DV, Szymczak-Workman AL, et al. Interleukin-35 limits anti-tumor immunity[J]. Immunity, 2016, 44(2):316-329. DOI: 10.1016/j.immuni.2016.01.013. doi:10.1016/j.immuni.2016.01.013
[15]	Zou JM, Qin J, Li YC, et al. IL-35 induces N2 phenotype of neutrophils to promote tumor growth[J]. Oncotarget, 2017, 8(20):33501-33514. DOI: 10.18632/oncotarget.16819. doi:10.18632/oncotarget.v8i20
[16]	Lee CC, Lin JC, Hwang WL, et al. Macrophage-secreted interleukin-35 regulates cancer cell plasticity to facilitate metastatic colonization[J]. Nat Commun, 2018, 9(1): 3763. DOI: 10.1038/s41467-018-06268-0. doi:10.1038/s41467-018-06268-0
[17]	Wang X, Liu X, Zhang Y, et al. Interleukin (IL)-39 [IL-23p19/Epstein-Barr virus-induced 3 (Ebi3)] induces differentiation/expansion of neutrophils in lupus-prone mice[J]. Clin Exp Immunol, 2016, 186(2):144-156. DOI: 10.1111/cei.12840. doi:10.1111/cei.12840
[18]	Wang X, Wei Y, Xiao H, et al. A novel IL-23p19/Ebi3 (IL-39) cytokine mediates inflammation in Lupus-like mice[J]. Eur J Immunol, 2016, 46(6):1343-1350. DOI: 10.1002/eji.201546095. doi:10.1002/eji.201546095
[19]	Floss DM, Schönberg M, Franke M, et al. IL-6/IL-12 cytokine receptor shuffling of extra- and intracellular domains reveals canonical STAT activation via synthetic IL-35 and IL-39 signaling[J]. Sci Rep, 2017, 7(1): 15172. DOI: 10.1038/s41598-017-15173-3. doi:10.1038/s41598-017-15173-3
[20]	Manning AA, Zhao L, Zhu Z, et al. IL-39 acts as a friend to pancreatic cancer[J]. Med Oncol, 2019, 36(1): 12. DOI: 10.1007/s12032-018-1236-y.
[21]	Guo Y, Cao W, Zhu Y. Immunoregulatory functions of the IL-12 family of cytokines in antiviral systems[J]. Viruses, 2019, 11(9): 772. DOI: 10.3390/v11090772.
[22]	Figueiredo ML, Figueiredo Neto M, Salameh JW, et al. Ligand-mediated targeting of cytokine interleukin-27 enhances its bioactivity in vivo[J]. Mol Ther Methods Clin Dev, 2020, 17:739-751. DOI: 10.1016/j.omtm.2020.03.022. doi:10.1016/j.omtm.2020.03.022
[23]	Carbotti G, Petretto A, Naschberger E, et al. Cytokine-induced guanylate binding protein 1 (GBP1) release from human ovarian cancer cancer cells[J]. Cancers(Basel), 2020, 12(2): 488. DOI: 10.3390/cancers12020488.
[24]	Le HT, Keslar K, Nguyen QT, et al. Interleukin-27 enforces regulatory T cell functions to prevent graft-versus-host disease[J]. Front Immunol, 2020, 11:181. DOI: 10.3389/fimmu.2020.00181. doi:10.3389/fimmu.2020.00181
[25]	Figueiredo Neto M, Liu S, Salameh JW, et al. Interleukin-27 gene delivery targeting IL-6Rα-expressing cells as a stress response therapy[J]. Int J Mol Sci, 2020, 21(3): 1108. DOI: 10.3390/ijms21031108. doi:10.3390/ijms21031108
[26]	Lavoie S, Chun E, Bae S, et al. Expression of free fatty acid receptor 2 by dendritic cells prevents their expression of interleukin 27 and is required for maintenance of mucosal barrier and immune response against colorectal tumors in mice[J]. Gastroenterology, 2020, 158(5):1359-1372.e9.DOI: 10.1053/j.gastro.2019.12.027. doi:10.1053/j.gastro.2019.12.027
[27]	Hu A, Ding M, Zhu J, et al. Intra-tumoral delivery of IL-27 using adeno-associated virus stimulates anti-tumor immunity and enhances the efficacy of immunotherapy[J]. Front Cell Dev Biol, 2020, 8:210. DOI: 10.3389/fcell.2020.00210. doi:10.3389/fcell.2020.00210
[28]	Hawley JE, Pan S, Figg WD, et al. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy[J]. Prostate, 2020, 80(4):336-344. DOI: 10.1002/pros.23948. doi:10.1002/pros.v80.4
[29]	Hemati M, Rasouli Nejad Z, Shokri MR, et al. IL-27 impact on NK cells activity: implication for a robust anti-tumor response in chronic lymphocytic leukemia[J]. Int Immunopharmacol, 2020, 82:106350. DOI: 10.1016/j.intimp.2020.106350. doi:10.1016/j.intimp.2020.106350
[30]	Rocha GA, de Melo FF, Cabral MMDA, et al. Interleukin-27 is abrogated in gastric cancer, but highly expressed in other Helicobacter pylori-associated gastroduodenal diseases[J]. Helicobacter, 2020, 25(1): e12667. DOI: 10.1111/hel.12667.
[31]	Manouchehri-Doulabi E, Abbaspour S, Rostami S, et al. Evaluating the mechanism underlying antitumor effect of interleukin 27 on B cells of chronic lymphocytic leukemia patients[J]. J Cell Physiol, 2020, 235(12):9424-9431. DOI: 10.1002/jcp.29747. doi:10.1002/jcp.v235.12
[32]	Zhu J, Liu JQ, Shi M, et al. IL-27 gene therapy induces depletion of Tregs and enhances the efficacy of cancer immunotherapy[J]. JCI Insight, 2018, 3(7):e98745. DOI: 10.1172/jci.insight.98745. doi:10.1172/jci.insight.98745

Regulation of IL-35, IL-39 and IL-27 in tumor microenvironment

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References32

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.
[2]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[3]	Liu Xiaodi, Su Jianfei, Zhang Jingxian, Wei Xueqin, Jia Yingjie.Research progress of myeloid-derived suppressor cells in tumor angiogenesis[J]. Journal of International Oncology, 2024, 51(1): 50-54.
[4]	Gu Huayan, Zhu Teng, Guo Guilong.Breast microbiota and breast cancer： present and future[J]. Journal of International Oncology, 2024, 51(1): 55-58.
[5]	Zhang Yuan, Bai Zhiyu, Li Qi, Feng Qinmei.Current status of research on exosomes in malignancies[J]. Journal of International Oncology, 2023, 50(8): 484-488.
[6]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng.Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance[J]. Journal of International Oncology, 2023, 50(4): 227-230.
[7]	Ding Hao, Ying Jintao, Fu Maoyong.Research progress of CAR-T in the treatment of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2023, 50(4): 231-235.
[8]	Cao Mengqing, Xu Zhiyong, Shi Yuting, Wang Kai.Role of tertiary lymphoid structures in tumor immune microenvironment regulation and anti-tumor therapy[J]. Journal of International Oncology, 2023, 50(3): 169-173.
[9]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[10]	Zhu Yi, Chen Jian.Mechanism of hydrogen sulfide in tumorigenesis and development and its donor-mediated anti-tumor effects[J]. Journal of International Oncology, 2023, 50(12): 729-733.
[11]	Xie Lulu, Ding Jianghua.Progress of immunotherapy-based strategy in triple-negative breast cancer[J]. Journal of International Oncology, 2023, 50(11): 672-676.
[12]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[13]	Ma Xueyan, Lu Lili, Sun Pengfei.Advances in the immune microenvironment in cervical cancer[J]. Journal of International Oncology, 2023, 50(1): 47-50.
[14]	Zhao Jianhao, Duan Yanchao.Research progress in the pathogenesis of extramedullary disease in multiple myeloma[J]. Journal of International Oncology, 2023, 50(1): 55-59.
[15]	Wu Jiayu, Liu Jiacheng.Research progress of radiomics toward lung adenocarcinoma manifesting as solitary ground glass nodule[J]. Journal of International Oncology, 2022, 49(8): 449-452.